Found: 93
Select item for more details and to access through your institution.
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 115, doi. 10.1007/s10637-021-01175-6
- By:
- Publication type:
- Article
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1755, doi. 10.1007/s10637-020-00936-z
- By:
- Publication type:
- Article
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 755, doi. 10.1007/s10637-019-00797-1
- By:
- Publication type:
- Article
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 658, doi. 10.1007/s10637-018-0690-x
- By:
- Publication type:
- Article
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 307, doi. 10.1007/s10637-018-0662-1
- By:
- Publication type:
- Article
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 1, p. 47, doi. 10.1007/s10637-016-0391-2
- By:
- Publication type:
- Article
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 5, p. 604, doi. 10.1007/s10637-016-0374-3
- By:
- Publication type:
- Article
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 432, doi. 10.1007/s10637-015-0207-9
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 225, doi. 10.1007/s10637-014-0174-6
- By:
- Publication type:
- Article
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 510, doi. 10.1007/s10637-013-0062-5
- By:
- Publication type:
- Article
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1201, doi. 10.1007/s10637-013-0004-2
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 891, doi. 10.1007/s10637-012-9887-6
- By:
- Publication type:
- Article
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 967, doi. 10.1007/s10637-013-9929-8
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0
- By:
- Publication type:
- Article
Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 3, p. 277, doi. 10.1002/ajh.22263
- By:
- Publication type:
- Article
A systematic review of the business case for corporate social responsibility and firm performance.
- Published in:
- Corporate Social Responsibility & Environmental Management, 2020, v. 27, n. 2, p. 444, doi. 10.1002/csr.1838
- By:
- Publication type:
- Article
Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2022, v. 54, n. 2, p. 315, doi. 10.4143/crt.2022.078
- By:
- Publication type:
- Article
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
- Published in:
- PLoS ONE, 2021, v. 16, n. 12, p. 1, doi. 10.1371/journal.pone.0261478
- By:
- Publication type:
- Article
Disclosure, Accountability and Performance: The Case of Ghanaian Banking Industry.
- Published in:
- International Journal of Management, Accounting & Economics, 2019, v. 6, n. 12, p. 844
- By:
- Publication type:
- Article
Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
- Published in:
- International Journal of Oncology, 2022, v. 61, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5404
- By:
- Publication type:
- Article
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
- Published in:
- Oncogene, 2005, v. 24, n. 46, p. 6861, doi. 10.1038/sj.onc.1208841
- By:
- Publication type:
- Article
Lung cancer and metastasis: new opportunities and challenges.
- Published in:
- Cancer & Metastasis Reviews, 2015, v. 34, n. 2, p. 169, doi. 10.1007/s10555-015-9562-4
- By:
- Publication type:
- Article
New strategies to develop new medications for lung cancer and metastasis.
- Published in:
- Cancer & Metastasis Reviews, 2015, v. 34, n. 2, p. 265, doi. 10.1007/s10555-015-9553-5
- By:
- Publication type:
- Article
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00164-5
- By:
- Publication type:
- Article
"I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Response to Martani, Tomasi, and Casanto.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients.
- Published in:
- Journal of Cachexia, Sarcopenia & Muscle, 2020, v. 11, n. 6, p. 1501, doi. 10.1002/jcsm.12625
- By:
- Publication type:
- Article
Genesis of Peace Education in an Era of Xenophobia and Terrorism: The Case of Africa.
- Published in:
- Journal of Pan African Studies, 2009, v. 2, n. 8, p. 260
- By:
- Publication type:
- Article
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
- Published in:
- Oncologist, 2020, v. 25, n. 6, p. 523, doi. 10.1634/theoncologist.2019-0574
- By:
- Publication type:
- Article
Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?
- Published in:
- Oncologist, 2019, v. 24, n. 11, p. e1148, doi. 10.1634/theoncologist.2019-0094
- By:
- Publication type:
- Article
Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.
- Published in:
- Oncologist, 2019, v. 24, n. 1, p. 96, doi. 10.1634/theoncologist.2017-0687
- By:
- Publication type:
- Article
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
- Published in:
- Oncologist, 2017, v. 22, n. 2, p. 189, doi. 10.1634/theoncologist.2016-0121
- By:
- Publication type:
- Article
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 660, doi. 10.1634/theoncologist.2014-0465
- By:
- Publication type:
- Article
Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers.
- Published in:
- Oncologist, 2011, v. 16, n. 6, p. 788, doi. 10.1634/theoncologist.2010-0380
- By:
- Publication type:
- Article
Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 10, p. 4932, doi. 10.1002/cam4.1749
- By:
- Publication type:
- Article
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 127, doi. 10.1007/s10637-024-01420-8
- By:
- Publication type:
- Article
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.
- Published in:
- Carcinogenesis, 2012, v. 33, n. 7, p. 1270, doi. 10.1093/carcin/bgs148
- By:
- Publication type:
- Article
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 324, p. 1, doi. 10.1126/scitranslmed.aad5640
- By:
- Publication type:
- Article
In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs.
- Published in:
- Therapeutic Advances in Medical Oncology, 2011, v. 3, n. 1, p. S37, doi. 10.1177/1758834011423403
- By:
- Publication type:
- Article
Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 9, p. 1121, doi. 10.1002/jcph.2053
- By:
- Publication type:
- Article
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 21, p. 5358, doi. 10.1002/cncr.27528
- By:
- Publication type:
- Article
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 6, p. 1262, doi. 10.1002/cncr.25526
- By:
- Publication type:
- Article
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
- Published in:
- 2010
- By:
- Publication type:
- journal article
A Front-Line Window of Opportunity Phase 2 Study of Sorafenib in Patients With Advanced Nonsmall Cell Lung Cancer.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 24, p. 5686, doi. 10.1002/cncr.25448
- By:
- Publication type:
- Article
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.
- Published in:
- 2009
- By:
- Publication type:
- journal article